Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?

Rosset, Rémy; Bratan, Flavie; Crouzet, Sébastien; Tonoli-Catez, Hélène; Mège‐Lechevallier, Florence; Gelet, A.; Rouvière, Olivier

doi:10.1007/s00330-016-4491-3

Cited by 13 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within targeted regions, the 3-week radiological and histological treatment efficacies were determined using 3-level structured destruction score classifications [12]. For MRI destruction scores, targeted regions completely included within the NPV without focal enhancement were classified as successful treatment (score 0), targeted regions not totally included within the NPV as targeting failure (score 1) and targeted regions within the NPV but demonstrating residual focal enhancement as ablative failure (score 2).…”

Section: Determination Of Treatment Efficacymentioning

confidence: 99%

“…As opposed to a series of brief small volume exposures in HIFU, directional ultrasound has distinct patterns of thermal dose and temperature deposition and subsequent tissue damage due to the use of continuous heating with an unfocused ultrasound beam. The ablated volume is visualized post-treatment on contrast enhanced MRI (CE-MRI) as a non-perfused-volume (NPV) indicating complete cell death [10][11][12]. Target tissue undergoes acute coagulation necrosis [13], followed by delayed necrosis, which is mainly dependent on cumulative thermal dose [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer

Anttinen

Mäkelä

Suomi

et al. 2019

Scandinavian Journal of Urology

View full text Add to dashboard Cite

Background: MRI-guided transurethral ultrasound ablation (TULSA) has been evaluated for organ-confined prostate cancer (PCa). The purpose of this study was to assess the safety and toxicity, accuracy and short-term evolution of cell-death after lesion-targeted TULSA. Methods: This prospective, registered, Phase-I treat-and-3-week-resect-study enrolled six patients with MRI-visible-biopsy-concordant PCa. Lesions were targeted using TULSA with radical intent, except near neurovascular bundles (NVB). Robot-assisted-laparoscopic-prostatectomy (RALP) was performed at 3 weeks. Post-TULSA assessments included MRI (1 and 3 weeks), adverse events and quality-of-life (QoL) to 3 weeks, followed by RALP and whole-mount-histology. Treatment accuracy and demarcation of thermal injury were assessed using MRI and histology. Results: Six patients (median age ¼ 70 years, prostate volume ¼ 60 ml, PSA ¼ 8.9 ng/ml) with eight biopsy-confirmed MRI-lesions (PIRADS 3) were TULSA-treated without complications (median sonication and MRI-times of 17 and 117 min). Foley-catheter removal was uneventful at 2-3 days. Compared to baseline, no differences in QoL were noted at 3 weeks. During follow-up, MRI-derived non-perfused-volume covered ablated targets and increased 36% by 3 weeks, correlating with necrosis-area on histology. Mean histological demarcation between complete necrosis and outer-limit-ofthermal-injury was 1.7 ± 0.4 mm. Coagulation necrosis extended to capsule except near NVB, where 3 mm safety-margins were applied. RALPs were uncomplicated and histopathology showed no viable cancer within the ablated tumor-containing target. Conclusions: Lesion-targeted TULSA demonstrates accurate and safe ablation of PCa. A significant increase of post-TULSA non-perfused-volume was observed during 3 weeks follow-up concordant with necrosis on histology. TULSA achieved coagulation necrosis of all targeted tissues. A limitation of this treat-and-resect-study-design was conservative treatment near NVB in patients scheduled for RALP.

show abstract

Section: Determination Of Treatment Efficacymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer

Anttinen

Mäkelä

Suomi

et al. 2019

Scandinavian Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Compared with light irradiation, the scattering of ultrasound in tissue is much weaker; thus it can penetrate much deeper without energy loss [22]. What is more, it can activate the sensitizers at their focal point with high spatial precision [18,23,24]. Nevertheless, little attention has been paid to the enhancement of its overall sonodynamic efficiency by considering quantum yield or tumor target ability.…”

Section: Introductionmentioning

confidence: 99%

MRI tracing non-invasive TiO₂-based nanoparticles activated by ultrasound for multi-mechanism therapy of prostatic cancer

Yuan

Song

2018

Nanotechnology

View full text Add to dashboard Cite

To reduce the side effects of chemotherapy and achieve effective and safe therapy for prostate cancer, herein a simple but multi-functional TiO:Gd@DOX/FA system activated by ultrasound was developed for the MRI-guided multi-mechanism therapy of prostate cancer. TiO nanoparticles served as a sonosensitizer as well as a nanocarrier with the pH-responsive release of DOX. The doping of Gd was not only able to endow the TiO with magnetic resonance imaging (MRI) ability, but also further improve the sonodynamic ability of the TiO. The characterization of the as-prepared TiO:Gd@DOX/FA showed sensitive pH-responsive drug release, high reactive oxygen species (ROS) production, T -MRI contrast performance and excellent biocompatibility. The cytotoxicity assay in vitro showed cell death up to 91.68% after 48 h incubation induced by the TiO:Gd@DOX + ultrasound group. Meanwhile, in the in vivo synergistic therapy studies, the tumor sizes of all the nanomedicine groups were smaller than for the free DOX (V:V = 4.2). More importantly, the body showed nearly no weight loss. This safety was also confirmed by the H&E staining, biodistribution experiment and serum biochemistry results. Altogether, TiO:Gd@DOX/FA significantly reduced the side effects of DOX, augmented the levels of ROS and achieved effective and safe therapy, indicating its potential for the multi-mechanism therapy of prostate cancer.

show abstract

“…To release the therapeutic cargo, a localised temperature increase by an externally controllable heat source such as high-intensity focused ultrasound (HIFU) or electrocauterisation is a promising trigger, allowing for a defined and well-controlled temperature increase at a specific location in a non- or minimally invasive fashion [22, 23]. HIFU, for instance, is clinically used for heat-induced tumour ablation with high spatial accuracy and a predefined target temperature [24, 25]. Moreover, it is generally combined with imaging modalities such as MRI or ultrasound in order to determine the exact localisation of the target lesions and to target the HIFU pulse [26–28].…”

Section: Introductionmentioning

confidence: 99%

An MRI-guided HIFU-triggered wax-coated capsule for supertargeted drug release: a proof-of-concept study

et al. 2019

View full text Add to dashboard Cite

Background Externally controlling and monitoring drug release at a desired time and location is currently lacking in the gastrointestinal tract. The aim of the study was to develop a thermoresponsive wax-coated capsule and to trigger its release upon applying a magnetic resonance imaging (MRI)-guided high-intensity focused ultrasound (HIFU) pulse. Methods Capsules containing a lyophilised gadolinium-based contrast agent (GBCA) were coated with a 1:1 (mass/mass) mixture of lanolin and cetyl alcohol (melting point ≈43 °C) and exposed to simulated gastric and intestinal fluids (United States Pharmacopoeia) at 37 °C for 2 and 24 h, respectively. In a HIFU gel phantom, wax-coated capsules ( n = 3) were tracked based on their T1- and T2-hypointensity by 1.5-T T1- and T2-weighted MRI pre- and post-exposure to an MRI-guided HIFU pulse. Results Lanolin/cetyl alcohol-coated capsules showed high resistance to simulated gastrointestinal fluids. In a gel phantom, an MRI-guided HIFU pulse punctured the wax coating, resulting in the hydration and release of the encapsulated lyophilised GBCA and yielding a T1-hyperintense signal close to the wax-coated capsule. Conclusion We provide the proof-of-concept of applying a non-invasive MRI-guided HIFU pulse to actively induce the disintegration of the wax-coated capsule, and a method to monitor the release of the cargo via T1-weighted MRI based on the hydration of an encapsulated lyophilised GBCA. The wax-coated capsule platform enables temporally and spatially supertargeted drug release via the oral route and promises to address a currently unmet clinical need for personalised local therapy in gastrointestinal diseases such as inflammatory bowel diseases and cancer. Electronic supplementary material The online version of this article (10.1186/s41747-019-0090-9) contains supplementary material, which is available to authorized users.

show abstract

Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?

Cited by 13 publications

References 38 publications

Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer

Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer

MRI tracing non-invasive TiO₂-based nanoparticles activated by ultrasound for multi-mechanism therapy of prostatic cancer

An MRI-guided HIFU-triggered wax-coated capsule for supertargeted drug release: a proof-of-concept study

Contact Info

Product

Resources

About

Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?

Cited by 13 publications

References 38 publications

Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer

Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer

MRI tracing non-invasive TiO2-based nanoparticles activated by ultrasound for multi-mechanism therapy of prostatic cancer

An MRI-guided HIFU-triggered wax-coated capsule for supertargeted drug release: a proof-of-concept study

Contact Info

Product

Resources

About

MRI tracing non-invasive TiO₂-based nanoparticles activated by ultrasound for multi-mechanism therapy of prostatic cancer